Project Summary
Tuberculosis (TB), caused by the bacterium, Mycobacterium tuberculosis, kills more humans every year than
does any other infectious disease, including HIV. Among the obstacles to eliminating TB is the lack of a
sufficiently-efficacious vaccine. Despite strong evidence for essential roles of CD4 T cells in TB immunity,
naturally-occurring T cell responses do not reliably eliminate the pathogen in TB, and we do not fully understand
the mechanisms that limit the effectiveness of CD4 T cell responses to M. tuberculosis. In earlier work, we
discovered that for optimal immune control, CD4 T cells must directly recognize and make intermolecular
contacts with M. tuberculosis-infected cells at the site of infection in the lungs. In light of this requirement for
intimate contact, we and others have found (in mice, nonhuman primates, and humans) that CD4 T cells are
located at the periphery of granulomas, rather than in the core where infected cells reside. We therefore
hypothesize that a major mechanism limiting immunity to TB is the failure of CD4 T cells to contact and engage
with infected cells, and that overcoming this failure will increase the efficacy of T cell immunity to TB. Several
potential mechanisms can explain the spatial separation of M. tuberculosis-infected cells and CD4 T cells in vivo,
yet these are not amenable to analysis using fixed, static images or cells removed from the granuloma
environment. Therefore, in this project, we propose to combine a unique multiphoton microscopy system for
intravital imaging, contained in a Biosafety Level 3 facility at the IPBS in Toulouse, with unique reporter mice and
M. tuberculosis strains developed and characterized at UCSF, to characterize interactions of antigen-specific
CD4 T cells with M. tuberculosis-infected and bystander cells in the lungs of live mice. The combination of these
innovative experimental systems allows us to test specific hypotheses that can account for the spatial and
functional separation of CD4 T cells and M. tuberculosis-infected cells in the lungs. The knowledge gained from
these studies will be used: 1) to inform design of experiments to define the molecular mechanisms that restrict
CD4 T cell interactions with M. tuberculosis-infected cells in vivo; 2) to provide the basis for studies comparing
distinct candidate TB vaccines, to determine which of them promote development of T cells that optimally access
M. tuberculosis-infected cells in granuloma cores. In additional experiments, we will extend recent findings
indicating important roles for innate lymphoid cells (ILC) in protective immunity to TB. Specifically, we will follow
up on findings that type 2 ILC (ILC2) undergo dramatic phenotypic transformations to ILC1-like cells in vivo in
response to M. tuberculosis infection, by live imaging of the interactions of ILC2 and ILC1-like cells with M.
tuberculosis-infected cells and with CD4 T cells, during the initial and the chronic stages of infection. Our studies
have high potential to provide valuable insights and new paradigms of immunity to TB, with the goal of informing
development of efficacious vaccines and host-directed therapies.